A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)
Authors
Keywords
-
Journal
GUT
Volume 65, Issue 1, Pages 91-99
Publisher
BMJ
Online
2015-03-13
DOI
10.1136/gutjnl-2015-309122
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tu1436 Development and Risk Factors of Post-Infectious Irritable Bowel Syndrome (PI-IBS) After Severe Outbreak of Enterocolitis Due to Enterohemorrhagic Escherichia coli (EHEC) O104:H4 in Germany 2011: A Cohort Study With Prospective Follow-up
- (2015) Viola Andresen et al. GASTROENTEROLOGY
- Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation
- (2014) N Waugh et al. HEALTH TECHNOLOGY ASSESSMENT
- Limited Risks of Major Congenital Anomalies in Children of Mothers With IBD and Effects of Medications
- (2013) Lu Ban et al. GASTROENTEROLOGY
- Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit
- (2013) David Tooth et al. GUT
- A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
- (2013) Klara Garsed et al. GUT
- Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care
- (2013) Polychronis Pavlidis et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier
- (2012) Cristina Martínez et al. GUT
- Intestinal barrier function in health and gastrointestinal disease
- (2012) M. Camilleri et al. NEUROGASTROENTEROLOGY AND MOTILITY
- Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome – a pilot study
- (2012) Ashok K. Tuteja et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome
- (2012) Robin Spiller et al. Journal of Neurogastroenterology and Motility
- IBS Patients Show Frequent Fluctuations Between Loose/Watery and Hard/Lumpy Stools: Implications for Treatment
- (2011) Olafur S Palsson et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Intestinal Serotonin Release, Sensory Neuron Activation and Abdominal Pain in Irritable Bowel Syndrome
- (2011) Cesare Cremon et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease
- (2010) R. C. Spiller et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome
- (2010) T. K. Klooker et al. GUT
- Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study
- (2009) R. CORINALDESI et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Mucosal Immune Activation in Irritable Bowel Syndrome: Gender-Dependence and Association With Digestive Symptoms
- (2009) Cesare Cremon et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Activation of Human Enteric Neurons by Supernatants of Colonic Biopsy Specimens From Patients With Irritable Bowel Syndrome
- (2009) Sabine Buhner et al. GASTROENTEROLOGY
- Postinfectious Irritable Bowel Syndrome
- (2009) Robin Spiller et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation